Controlling drug-to-antibody ratio and scalable reactors are key to reliable antibody-drug conjugate manufacturing success.

Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

TOKYO, March 12, 2026 3 FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in ...

Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ /6821.HK), recently announced that its Fengxian commercial ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.